RESULT OF A CLINICAL PHASE II TRIAL OF MABTHERA IN 30 CHINESE B CELL LYMPHOMAS PATIENTS
Abstract：OBJECTIVES: To observe clinical efficacy and adverse effects of MabThera in Chinese B cell lymphomas patients. METHODS: MabThera was administered 375 mg/m2 intravenous infusion every week for 4 weeks. RESULTS: 31 B cell lymphoma patients were entered, one patient was not able to observe further due to severe abnormal hepatic function after one week of treatment. Among 30 evaluable cases, three reached complete remission, 10 with partial remission, 12 no effect and 5 with progression, response rate being 43 %. The adverse effects were fever (9 patients), fatigue (5patients), skin rash (1 patient), liver function impairment (1 patient), and hypotention (1 patient).No bone marrow suppression was observed. CONCLUSION: Clinical results show that MabThera is a effective new drug for B cell lymphomas and the adverse effects were well tolerated by patients.
Keywords：B cell lvmphomasrituximabMabThera
Publication Date：1999-01-01
Online Publishing Date：2026-08-14(First online date of this platform, not the publication date of the document)
Pages：3( 822-824 )